HIV

;

Support for PrEP DC Act of 2025 (B26-0159)

Oct 30, 2025

Today we testify in support of the PrEP DC Act of 2025 (B26-0159) introduced by Councilmember Zachary Parker and co-introduced by eight other councilmembers. As the District continues to make progress in reducing the number of HIV infections, it must do everything possible in its power to ensure people who have a reason to protect themselves against HIV have access to all available prevention tools. That includes PrEP, which are incredible drugs that prevent HIV if people can access and afford them.

read more

Follow-up letter to Delta on employee plan coverage of PrEP

Oct 1, 2025

In July, we wrote to you to urge you you to cover all PrEP medications and services without cost-sharing, and not to employ prior authorization for the purpose of steering employees to one PrEP drug or another, as is required of all non-grandfathered commercial insurance plans in the United States. On August 23, 2025, you replied, assuring us that the enrollee notice we had brought to your attention had been “sent inadvertently,” and that Delta would “cover all three formulations of PrEP without cost-sharing subject to the terms and conditions of the plans.”  Unfortunately, we now have learned that Delta Air Lines intends to impose prior authorization requirements to steer employees and their family members who use PrEP to the generic formulation of PrEP effective October 1, 2025.

read more

HIV Groups letter to CVS Health on not covering Yeztugo

Sep 18, 2025

We, the undersigned 64 organizations, on behalf of people and communities affected by HIV, their care providers, public health practitioners, and community-based organizations, write in response to statements made by CVS Health to the media that it does not intend to cover Yeztugo (lenacapavir), a twice-yearly long-acting injectable drug recently approved by the FDA as pre-exposure prophylaxis (PrEP) for the prevention of HIV.[1]  We urge you to reconsider this decision and cover Yeztugo without delay.

read more

Testimony to Massachusetts Joint Committee on Financial Services on Bills to Address Barriers to HIV Medication

Sep 17, 2025

On behalf of the HIV+Hepatitis Policy Institute, we respectfully submit this testimony in support of H.1245/S.717: An Act to address barriers to HIV prevention medication. PrEP is a key component of both Massachusetts and federal strategies to end the HIV epidemic. But thirteen years after the introduction of PrEP, only a third of those who would benefit from PrEP are on it, with stark racial, ethnic, and gender disparities in uptake.

read more

Comment to HRSA on enrollment and re-certification of entities in the 340B drug pricing program

Sep 5, 2025

The HIV+Hepatitis Policy Institute submits this comment in support of HRSA’s proposed documentation and registration updates for Sexually Transmitted Disease (STD) grantees and subgrantees participating in the 340B Drug Pricing Program. STI clinics are a key setting for HIV testing and prevention services, including PrEP and PEP, as well as for testing and treatment for viral hepatitis, especially hepatitis C. As longstanding advocates for the 340B program, we believe strong oversight and clear documentation are critical to preserving its integrity and ensuring it continues to serve its core mission: supporting safety net providers and expanding access to care for low-income and underserved populations, including people with or at risk of HIV and hepatitis.

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest